M. Maral Mouradian, MD
Founder, President and Chair of the Board
Dr. Mouradian is an internationally recognized physician-scientist with an established research program in neurodegenerative disorders focused on Parkinson’s disease. Her original investigations at the US National Institutes of Health (NIH) pointed to fundamental alterations in the response to L-dopa with advancing disease resulting in the emergence of dyskinesias. She brings her expertise in this field to support MentiNova’s scientific and clinical development strategies. Dr. Mouradian currently holds an endowed chair at Rutgers – Robert Wood Johnson Medical School, directs its Center for Neurodegenerative and Neuroimmunologic Diseases and serves as the Editor-in-Chief of the journal Neurotherapeutics. After completing neurology residency, she received research training at the NIH in clinical neuropharmacology with Thomas N. Chase and in molecular biology with the Nobel Laureate Marshall Nirenberg.
Steven Braithwaite, PhD
Dr. Braithwaite is an experienced R&D executive in the field of neuroscience. Leading innovative approaches at biotechnology companies including Alkahest and Circuit Therapeutics and heading the cellular neurodegeneration group at Wyeth/Pfizer have provided Dr. Braithwaite the experience to drive MentiNova’s business and research strategies. His primary therapeutic interests are in the areas of Parkinson’s disease, Alzheimer’s disease and related neurodegenerative disorders. He actively publishes and serves on review panels with the NIH and the Michael J. Fox Foundation for Parkinson’s Research. Dr. Braithwaite is a graduate of the University of Cambridge, UK, received his PhD from the University of Bristol, UK and performed postdoctoral work at Stanford University.
James M. Golubieski
Board Member and Advisor
Mr. Golubieski is the President of New Jersey Health Foundation and its affiliate, Foundation Venture Capital Group (FVCG). As the President of Foundation Venture Capital Group, he works closely with the companies in which FVCG has invested, sits on their Boards and provides guidance in helping them to develop their business models. Previously he had been the CFO of Array Medical, Inc., a medical device start-up company established in 1995 that developed a groundbreaking blood test for platelet function. The company was sold in 1999. Mr. Golubieski was also the Chief Operating Officer and Senior Executive Vice President of Glendale National Bank and a member of its Board of Directors, President of Glendale Investment Corp and Glendale Mortgage Services, Inc., and Chief Financial Officer of Glendale Bancorp, which was acquired by Mellon Financial. For 10 years prior to that he had been with KPMG.
George F. Heinrich, MD
Dr. Heinrich is the Vice Chair and Chief Executive Officer of New Jersey Health Foundation and its affiliate, Foundation Venture Capital Group. He received his MD degree from New Jersey Medical School and served his residency in Internal Medicine at Martland Hospital in Newark. He has dedicated his career to the advancement of medical research and education and has served in a variety of capacities on many boards including those of hospitals, medical centers, nursing homes and charitable organizations within New Jersey and New York.